Appropriate Frequency and Interval of Neck Ultrasonography Surveillance during the First 10 Years after Total Thyroidectomy in Patients with Papillary Thyroid Carcinoma

Yoo Jin Lee1, Dong Wook Kim1*, Gi Won Shin1, Young Jin Heo1, Jin Wook Baek1, Young Jun Cho1, Young Mi Park1, Ha Kyoungh Park2, Tae Kuwon Ha2, Do Hun Kim2, Soo Jin Jung3, Ji Sun Park4, Ki Jung Ahn5 and Hye Jin Baek7

1 Department of Radiology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, 2 Department of General Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, 3 Department of Otorhinolaryngology-Head and Neck Surgery, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, 4 Department of Nuclear Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, 5 Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, 6 Department of Radiation Oncology, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Hospital, Changwon, South Korea

*Correspondence: Dong Wook Kim
dwultra@nate.com

Background: No previous study has employed the frequency and interval of follow-up ultrasonography (US) during the first 10 years after total thyroidectomy in patients with papillary thyroid carcinoma (PTC). The aim of this study was to determine the appropriate frequency and interval of follow-up US during the first 10 years in patients who have undergone total thyroidectomy for PTC.

Methods: Two hundred seventy-two patients underwent total thyroidectomy for PTC at our institution from January 2006 to December 2007. Nineteen patients were excluded because of lack of US follow-up data for the neck. Follow-up US was performed by one of two radiologists in all patients. Tumor recurrence/persistence was confirmed by histopathology.

Results: The mean interval between surgery and the final follow-up US examination was 79.0 months, and the mean number of follow-up US sessions was 5.9 in the 253 evaluable patients. Eleven patients (4.3%) developed tumor recurrence/persistence, which was detected on follow-up US within 5 years after total thyroidectomy in all cases. T and N stages were independently associated with tumor recurrence/persistence. The interval between surgery and first suspicion of tumor recurrence/persistence on follow-up US was ≤12 months in six patients and 20, 35, 41, 53, and 60 months in the remaining five patients.

Conclusion: For detection of tumor recurrence/persistence after total thyroidectomy in patients with PTC, one or two sessions of follow-up US during the first 2 years, depending on T and N stages and one session of follow-up US in every second year during the following 8 years may be appropriate.

Keywords: papillary thyroid carcinoma, total thyroidectomy, ultrasonography, surveillance, recurrence
INTRODUCTION

Up to 20% of patients with differentiated thyroid carcinoma develop locoregional recurrence (1, 2), which is fatal in 8% of cases (3). Ultrasonography (US) has been reported to have higher sensitivity for detection of postoperative recurrences of thyroid cancer in the neck than serum thyroglobulin or diagnostic whole-body scanning (4–7). Further, neck US is recommended as the first-line follow-up method in patients with differentiated thyroid cancer (4, 7). The recently published American Thyroid Association guidelines emphasize the role of neck US in follow-up of patients with papillary thyroid carcinoma (PTC) (8). In the current guidelines, it is recommended that these patients undergo neck US at least annually as part of routine follow-up, starting as early as 6 months after surgery, for detection of tumor recurrence or persistence (4, 8–10). However, the evidence for this short US follow-up interval is weak, and overuse of follow-up US examinations has economic implications.

In a recent multicenter study of follow-up US after total thyroidectomy for the treatment of PTC, the majority (66.1%) of cases of recurrence/persistence were detected within the first 2 years after total thyroidectomy (11). The authors of that study suggested that the optimal interval between thyroid surgery and the first US follow-up examination was 1–2 years and that one or two US surveillance examinations during the first five postoperative years may be appropriate (11). However, to the best of our knowledge, there have been no reports on the appropriate frequency and interval of US follow-up during the first 10 years after total thyroidectomy in patients with PTC. The aim of this study was to determine the appropriate frequency and interval of follow-up US during the first 10 postoperative years in patients who have undergone total thyroidectomy for PTC.

PATIENTS AND METHODS

Patients

Two hundred seventy-two patients [252 women, 20 men; mean age 53.9 ± 12.1 (range 20–87) years] underwent total thyroidectomy for PTC at our hospital from January 2006 to December 2007. All patients routinely underwent postoperative neck US for detection of tumor recurrence/persistence or nodal metastasis. The patients who had undergone total thyroidectomy in 2007 had been included in a previous multicenter study that assessed postoperative tumor recurrence/persistence during 5 years of follow-up (11), which was extended to more than 10 years in this study. Nineteen of the 272 patients did not undergo postoperative follow-up US, so were excluded from the study, leaving data on 253 patients [234 women, 19 men; mean age 53.8 ± 12.0 (range 20–87) years] available for analysis. The institutional review board at our hospital approved the protocol used in this study (IRB: 17-0211). The need for informed consent was waived because of the retrospective nature.

Total Thyroidectomy and Histopathology

In all cases, total thyroidectomy was performed by one of two surgeons with different levels of experience performing thyroid surgery (27 and 3 years). At our hospital, the extent of thyroid surgery is determined by multiple factors, including patient age, family history, tumor size, extrathyroidal tumor extension, nodal metastasis, and patient agreement. Total thyroidectomy was performed for patients with PTC and suspected perithyroidal tumor invasion or suspicious nodal metastasis on preoperative imaging, i.e., US or computed tomography. On histopathological analysis, the location and size of the primary PTC, perithyroidal extension, nodal metastasis, and multifocality were investigated. T and N stages were investigated on the basis of the eighth edition of the American Joint Committee on Cancer staging system (12).

Follow-up US

Two experienced radiologists (undertaking more than 2,000 thyroid and neck US procedures per year) performed the follow-up US examinations of the neck using a high-resolution ultrasound instrument (HDI 5000 or iU 22; Philips Medical Systems, Bothell, WA, USA) equipped with a 5–15-MHz linear probe. At our hospital, follow-up neck US is routinely performed at 1- or 2-year intervals in patients who have undergone surgery for PTC. Features investigated on follow-up US examinations include the presence of a newly developed mass in the neck area, the presence of a suspicious lymph node in the neck, and interval change of the previous mass or lymph node in the neck. Known US features of nodal metastasis from PTC include diffusely increased echogenicity, intranodal microcalcifications, and an intranodal cystic component (13, 14).

Tumor Recurrence/Persistence

In October 2017, single radiologist (DWK) retrospectively investigated US findings and histopathological results using a picture archiving and communication system and electronic medical records, respectively. Tumor recurrence/persistence was classified as non-nodal or nodal: non-nodal tumor recurrence/persistence was defined as the presence of a newly developed PTC in the postoperative thyroid bed, or perithyroidal neck area on histopathologic examination and nodal tumor recurrence/persistence was defined as nodal metastasis from PTC. Tumor recurrence/persistence was determined using US-guided fine-needle aspiration, core needle biopsy, or surgery for a suspicious neck mass or lymph node detected on follow-up US after total thyroidectomy.

Statistical Analysis

The data were assessed for normality using the Kolmogorov–Smirnov test. Patient age, primary tumor size, number of follow-up sessions, and interval of postoperative US examinations are expressed as the mean ± SD. Differences in clinical and radiologic features between patients who did and did not develop tumor recurrence/persistence were evaluated using the independent t-test and Pearson’s χ² test; for small cell values, Fisher’s exact test was used. Multivariate logistic regression analysis was used to determine the predictive power of individual clinical and radiologic features. The diagnostic performance of each potential predictor of tumor recurrence/persistence was evaluated by receiver-operating characteristic curve analysis. A cutoff value for each predictor was determined by maximizing the sum of
sensitivity and specificity. The area under the receiver-operating characteristic curve was computed using the logistic regression model output. The statistical analyses were performed using SPSS version 24.0 (IBM Corp., Armonk, NY, USA) and MedCalc version 14.10 (MedCalc Software, Ostend, Belgium). A p value < 0.05 was considered to be statistically significant.

RESULTS

The mean size of the primary PTC in the 253 patients was 12.3 ± 7.8 (range 2.0–45.0) mm. The primary PTC was located in the right lobe in 119 patients, the left lobe in 129, and the isthmus in 5. The T stage was T1a in 107 patients, T1b in 107, T2 in 31, T3a in 3, T3b in 5, T4a in 0, and T4b in 0. The N stage was N0 in 158 patients, N1a in 72, and N1b in 23. Multifocality and bilaterality were observed in 91 and 78 patients, respectively. The mean interval between total thyroidectomy and the last follow-up US examination was 79.0 ± 39.2 (range 5–137) months, and the mean number of follow-up US sessions was 5.9 ± 2.8 (range 1–14).

Eleven (4.3%) of the 253 patients had tumor recurrence/persistence, which was nodal in 10 (Figure 1) and non-nodal in one. Tumor recurrence/persistence was confirmed by surgical excision after US-guided fine-needle aspiration. The mean largest diameter of the primary PTC and the recurrent/persistent lesion as measured on US was 16.1 (range 5.0–30.0) mm and 9.3 (range 4.9–15.4) mm, respectively. The majority (7/11, 63.6%) of recurrent/persistent lesions were subcentimetric in the largest diameter.

The clinical, US, and histopathologic findings in patients with and without tumor recurrence/persistence are compared in Table 1. There was a significant difference in T and N stages (P < 0.0001) and number of follow-up US sessions (P = 0.001) between the two groups, but not in patient age or sex, size, or location of the primary PTC, multifocality, or interval between surgery and the final follow-up US (P > 0.05).

The results for follow-up US and tumor recurrence/persistence are shown in Table 2. There was variation in the number of follow-up US sessions and in the interval between surgery and the last US follow-up examination. The interval between total thyroidectomy and the last follow-up examination was 120 months or more in 64 (25.3%) of the 253 patients. In the 11 patients with tumor recurrence/persistence, the mean interval between total thyroidectomy and the first detection of tumor recurrence/persistence on follow-up US was 23.5 ± 20.2 (range 6–60) months. In six (54.5%) of these patients, tumor recurrence/persistence was detected on follow-up US during the first postoperative year [mean 8.2 (range 6–11) months]; in the remaining five patients, the intervals until first detection of tumor recurrence/persistence on follow-up US were 20, 35, 41, 53, and 60 months.

In multivariate logistic regression analysis, T and N stages were significantly and independently associated with tumor recurrence/persistence (Table 3). Similarly, in the receiver-operating characteristic curve analysis, T and N stages showed

![Figure 1](https://example.com/figure1.png)
Location of primary PTC 0.077 (mm, mean ± SD)  
Size of primary PTC 1.13 (0.96, 1.33) 0.137 
Age (years, mean ± SD) 3.47 (1.15, 10.42) 0.027 
Multifocality 1.45 (0.85, 1.45) 0.172 
Interval of the last follow-up US 1.03 (0.97, 1.08) 0.357 
Number of follow-up US session 1.45 (0.96, 3.28) 0.069 

*Numbers in parentheses are 95% confidence intervals.  
PTC, papillary thyroid carcinoma; US, ultrasonography.

| Items | Odds ratio* | p Value |
|-------|-------------|---------|
| Patient age | 1.03 (0.96, 1.10) | 0.459 |
| Sex | NA | NA |
| Location of primary PTC | 1.13 (0.96, 1.33) | 0.137 |
| T stage | 2.33 (0.54, 10.12) | 0.261 |
| N stage | 4.24 (1.35, 13.33) | 0.013 |
| Multifocality | 1.45 (0.85, 1.45) | 0.172 |
| Interval of the last follow-up US | 1.03 (0.97, 1.08) | 0.357 |
| Number of follow-up US session | 1.45 (0.96, 3.28) | 0.069 |

*Numbers in parentheses are 95% confidence intervals.  
PTC, papillary thyroid carcinoma; US, ultrasonography.

| Items | Avalue* | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Cutoffb | p Value |
|-------|---------|----------------|----------------|---------|---------|---------|---------|
| T stage | 0.722 | 63.6 | 86.8 | 17.9 | 98.1 | >T1b | 0.031 |
| N stage | 0.807 | 90.9 | 64.9 | 10.5 | 99.4 | >N0 | <0.0001 |

*Az indicates the largest area under the receiver-operating characteristic curve.  
*Cutoff value demonstrated no metastasis as 0, N1a as 1, and N1b as 2.  
Numbers in parentheses are 95% confidence intervals.  
PPV, positive predictive value; NPV, negative predictive value.

Data are number of nodules, with percentage in parentheses.  
NA, not applicable; TRP, tumor recurrence/persistence; PTC, papillary thyroid carcinoma; US, ultrasonography.

| Items | TRP (-) (n = 242) | TRP (+) (n = 11) | p Value |
|-------|------------------|-----------------|---------|
| Age (years, mean ± SD) | 54.1 ± 11.8 | 47.2 ± 13.3 | 0.122 |
| Sex (women:men) | 223:19 | 11.0 | 1.000 |
| Size of primary PTC (mm, mean ± SD) | 12.2 ± 7.8 | 16.1 ± 7.7 | 0.104 |
| Location of primary PTC | 0.077 |
| Right | 112 (46.3) | 7 (63.6) |
| Left | 126 (52.1) | 3 (27.3) |
| Isthmus | 4 (1.7) | 1 (9.1) |
| T stage | <0.0001 |
| T1a | 104 (43.0) | 3 (27.3) |
| T1b | 106 (43.8) | 1 (9.1) |
| T2 | 27 (11.2) | 4 (36.4) |
| T3a | 1 (0.4) | 2 (18.2) |
| T3b | 4 (1.7) | 1 (9.1) |
| T4a | 0 (0) | 0 (0) |
| T4b | 0 (0) | 0 (0) |
| N stage | <0.0001 |
| N0 | 157 (64.9) | 1 (9.1) |
| N1a | 66 (27.3) | 6 (54.5) |
| N1b | 19 (7.9) | 4 (36.4) |
| Multifocality | 0.264 |
| Absence | 157 (64.9) | 5 (45.5) |
| Presence | 85 (35.2) | 6 (54.5) |
| Number of follow-up US session (mean ± SD) | 5.8 ± 2.7 | 8.5 ± 2.4 | 0.001 |
| Interval to the last follow-up US (mean ± SD) | 78.0 ± 39.2 | 99.8 ± 34.1 | 0.08 |

Data are number of nodules, with percentage in parentheses.  
NA, not applicable; TRP, tumor recurrence/persistence; PTC, papillary thyroid carcinoma; US, ultrasonography.

| Number of follow-up US sessions | Interval of the last follow-up US (month: mean ± SD, range) | Tumor recurrence/persistence (n) |
|--------------------------------|-------------------------------------------------|--------------------------------|
| 1 (n = 18) | 16.9 ± 14.7 (5–55) | 0 |
| 2 (n = 22) | 23.4 ± 6.8 (10–37) | 0 |
| 3 (n = 18) | 34.8 ± 9.0 (16–54) | 1 |
| 4 (n = 18) | 45.9 ± 12.4 (27–71) | 0 |
| 5 (n = 34) | 66.0 ± 15.8 (36–122) | 0 |
| 6 (n = 24) | 91.8 ± 23.9 (61–126) | 0 |
| 7 (n = 39) | 99.3 ± 17.7 (64–128) | 2 |
| 8 (n = 42) | 114.0 ± 11.6 (91–137) | 1 |
| 9 (n = 17) | 120.1 ± 8.5 (101–133) | 4 |
| 10 (n = 11) | 120.6 ± 8.1 (106–133) | 1 |
| 11 (n = 6) | 122.5 ± 8.8 (106–134) | 1 |
| 12 (n = 3) | 118.7 ± 12.7 (104–127) | 1 |
| 13 (n = 0) | 0 (0) | 0 |
| 14 (n = 1) | 127 (127) | 0 |

US, ultrasonography.

have undergone total thyroidectomy for PTC (8, 9). To date, the role of neck US is particularly important in patients who have remnant thyroid tissue after total thyroidectomy for PTC (15). In the literature, less than 1–2% of low-risk patients and 8% of intermediate-risk patients were identified to have structural recurrence/persistence of PTC (8), which involved lymph nodes in the neck in the majority of cases (60–75%) (1). In this study, the rate of tumor recurrence/persistence was 4.3% (11/253), which is within the range reported previously (8).

Known risk factors for recurrence of PTC include a large primary tumor, extrathyroidal invasion, advanced T stage, and advanced N stage (11, 16, 17). In this study, the risk factor for tumor recurrence/persistence was advanced T and N stages. The reason for this difference is unclear, but it may relate to the low prevalence of a large primary tumor and the low rate of tumor recurrence/persistence in our study.

All our cases of tumor recurrence/persistence were detected on follow-up US within 5 years after total thyroidectomy, and the majority (72.7%, 8/11) were detected on follow-up US within the first 3 years after surgery. Our findings suggest that the frequency of follow-up US examinations for detection of tumor recurrence in the 1–10 years after total thyroidectomy should be selected according to the T and N stages. However, our study included a small number of patients with high T and N stage disease. Therefore, we recommend one or two follow-up US examinations during the first 2 years, depending on T and N stages and

**DISCUSSION**

Neck US is the current gold standard for postoperative surveillance to detect tumor recurrence/persistence in patients who have undergone total thyroidectomy for PTC (8, 9). Therefore, we recommend one or two follow-up US examinations during the first 2 years, depending on T and N stages and...
one follow-up US examination in every second year during the subsequent 8 years.

This study had several limitations. First, not all patients underwent a final follow-up US examination >10-year period. In 189 patients (74.7%), the period between total thyroidectomy and the final follow-up US was less than 10 years. Second, the frequency and interval of follow-up US were variable and irregular. Third, not all the patients who underwent total thyroidectomy during the study period were included in the analysis. Of the 272 eligible patients, 19 (7.0%) were excluded because of absence of postoperative follow-up US. Fourth, no data for serology, radioactive iodine ablation therapy, computed tomography, or whole-body scans with radiiodine could be included. Finally, interobserver variability between the two radiologists who performed the follow-up US examinations could not be assessed because of the low prevalence of tumor recurrence/persistence in the study.

In conclusion, this study demonstrated a low rate of tumor recurrence/persistence after total thyroidectomy for PTC, that only T and N stages had a significant association with tumor recurrence/persistence, and that the majority of patients with recurrence/persistence were detected on follow-up US within 3 years after total thyroidectomy. Thus, annual follow-up US examinations of the neck for detection of tumor recurrence/persistence in the first 10 years after total thyroidectomy may be excessive. Therefore, we recommend one or two sessions of follow-up US during the first 2 years after total thyroidectomy, depending on T and N stages and one session of follow-up US in every second year during the subsequent 8 years. A large-scale multicenter study is required to confirm our hypothesis.

**REFERENCES**

1. Shlumberger MJ. Papillary and follicular thyroid carcinoma. *N Engl J Med* (1998) 338:297–306. doi:10.1056/NEJM19980223380506
2. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. *Thyroid* (1999) 9:421–7. doi:10.1089/thy.1999.9.421
3. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. *J Clin Endocrinol Metab* (1990) 71:414–24. doi:10.1210/jcem-71-2-414
4. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. *Cancer* (2003) 97:90–6. doi:10.1002/cncr.11031
5. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. *J Clin Endocrinol Metab* (2003) 88:3668–73. doi:10.1210/jc.2002-021925
6. Torlontano M, Crocetti U, D’Aloisio L, Bonfitto N, Di Giorgio A, Modoni S, et al. Serum thyroglobulin and 131I whole body scan after recontamination human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. The role for neck ultrasonography. *Eur J Endocrinol* (2003) 148:18–24. doi:10.1530/eje.0.1480019
7. Torlontano M, Attard M, Crocetti U, Timino S, Bruno R, Costante G, et al. Follow-up of low-risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. *J Clin Endocrinol Metab* (2004) 89:3402–7. doi:10.1210/jc.2003-031521
8. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* (2016) 26:1–133. doi:10.1089/thy.2015.0020
9. Pacini F, Schlumberger M, Dvallie H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* (2006) 154:787–803. doi:10.1530/eje.1.02158
10. Zaheer S, Tan A, Ang ES, Loke KS, Kao YH, Goh A, et al. Post-thyroidectomy neck ultrasonography in patients with thyroid cancer and a review of the literature. *Singapore Med J* (2014) 55:177–82. doi:10.11622/smedj.2014050

**ETHICS STATEMENT**

All study participants waived informed consents owing to the retrospective analysis, and the study design was approved by the appropriate ethics review boards.

**AUTHOR CONTRIBUTIONS**

Concept and design: DWK. Acquisition of data: YJL and DWK. Literature review and refinement of manuscript: all the authors. Analysis and interpretation of data: HJB and DWK. Manuscript writing: YJL and DWK. Review of final manuscript: DWK.

**ACKNOWLEDGMENTS**

This work was supported by the 2017 Inje University research grant.

Copyright © 2018 Lee, Kim, Shin, Heo, Baek, Cho, Park, Park, Ha, Kim, Jung, Park, Ahn and Baek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.